人类 T 细胞嗜淋巴细胞病毒 1 型 (HTLV-1) 与成人 T 细胞白血病/淋巴瘤 (ATLL)（一种胎儿恶性感染）有关。最近，HTLV-1新的无症状职业（AC）在献血者中频繁报道。了解 HTLV-1 相关分子发病机制的深刻概念可能会导致寻找新的治疗策略。目前的研究旨在确定 ATLL 中与白血病相关的信号调节。30 名参与者分为三组进行评估，其中包括 10 名 ATLL 患者、10 名 AC 和 10 名正常对照。从没有任何化疗史的 ATLL 患者中分离出血液样本。此外，还从 AC 和正常个体中回收了血液样本。对收集的血液样本进行淋巴细胞分离。此后，从制备的样品中提取RNA并用于cDNA合成。使用实时PCR研究了Tax和HBZ作为病毒基因和细胞基因，包括MKP-1、EVI-1、JNK-1、FOXO-1、AKT-1、DEPTOR、MTOR和JUN。 ATLL 患者年龄为 53.2 ± 7.32 岁，其中 9 例（90%）为男性。与内部对照相比，EVI-1 和 FOXO-1 表达水平与 ATLL 患者显着相关。然而，在其余组中没有看到其他基因表达的显着差异。发现调节HTLV-1转化的病毒和细胞信号通路至关重要。可以考虑采用一种新的治疗策略来调节体内 ATLL 细胞信号通路。因此，建议使用相关细胞信号通路的激活剂和抑制剂进行 ATLL 细胞治疗的临床试验。建议对 FOXO-1 和 EVI-1 进行更多研究，以靶向这些基因，以揭示 ATLL 的分子发病机制。

Human T-cell lymphotropic virus type 1 (HTLV-1) is associated with adult T-cell leukemia/lymphoma (ATLL), a fetal malignant infection. Recently, The HTLV-1 new Asymptomatic careers (ACs) have frequently been reported among blood donors. Reaching the profound concept of HTLV-1-associated molecular pathogenesis could result in finding novel therapeutic strategies. The current study aimed to determine leukemia-related signaling regulation in ATLL.30 participants were evaluated in three groups, including 10 ATLL patients, 10 ACs, and 10 normal controls. Blood samples were isolated without any chemotherapy history from ATLL patients. Also, blood samples were recovered from ACs and normal individuals. Lymphocyte isolation was done on collected blood samples. After this, RNA was extracted from the prepared samples and utilized for the cDNA synthesis. Tax and HBZ as viral genes and cellular genes, including MKP-1, EVI-1, JNK-1, FOXO-1, AKT-1, DEPTOR, MTOR, and JUN, were investigated using real-time PCR.The mean age of ATLL patients was 53.2 ± 7.32 years, and 9 (90%) were male. The EVI-1 and FOXO-1 expression levels were significantly associated with ATLL patients compared to internal control. However, the significant differences in expression of other genes in the remaining groups were not seen.Discovering viral and cellular signaling pathways that regulate HTLV-1 transformation is essential. A novel therapeutic strategy for ATLL regulating cellular signaling pathways in vivo could be considered. Therefore, clinical trials using activators and inhibitors of related cellular signaling pathways for cell therapy of ATLL are recommended. It is recommended more investigation on FOXO-1 and EVI-1 for targeting these genes to reveal the molecular pathogenesis of ATLL.